Source: Virtual Congress 2020 – Prognosis and biomarkers of idiopathic pulmonary fibrosis
Disease area: Interstitial lung diseases



Rating:

Share or cite this content

Citations should be made in the following way:
. d'Alessandro (Siena, Italy), L. Bergantini (Siena, Italy), P. Cameli (Siena, Italy), A. Carleo (Hannover, Germany), P. Sestini (Siena, Italy), E. Bargagli (Siena, Italy). Neutrophil-to-lymphocyte ratio in IPF patients: a novel prognostic biomarker?. 823

Member's Comments

No comment yet.

Related content which might interest you: Defining the role of neutrophil-to-lymphocyte ratio in COPD patients Source: Virtual Congress 2020 – Prognosis and integrated management of COPD Year: 2020 The evaluation of serum biomarkers in patients with sarcoidosis: Can visfatin be a new biomarker for sarcoidosis? Source: International Congress 2017 – Rare diseases Year: 2017 The prognostic value of the albumin-to-fibrinogen ratio in lung cancer patients. Source: International Congress 2019 – Biology and prognosis of lung cancer Year: 2019 Is FEV1/FEV6 ratio a reliable  tool in COPD diagnosis ? Source: Virtual Congress 2021 – Biomarkers to phenotype COPD: prediction of exacerbations Year: 2021 Mortality risk prediction in COPD by a prognostic biomarker panel Source: Eur Respir J 2014; 44: 1557-1570 Year: 2014 Is YKL-40 a prognostic marker in sarcoidosis? Source: Annual Congress 2010 - Biomarkers in diffuse parenchymal lung disease Year: 2010 Is neutrophil/lymphocyte ratio at the time of diagnosis a valuable prognostic factor in non-small cell lung cancer? Source: International Congress 2018 – Lung cancer: novel prognostic markers and scores Year: 2018 Clinical phenotyping of COPD patients: a simple tool with prognosis value Source: International Congress 2018 – COPD phenotypes: a1 antitrypsin deficiency and beyond Year: 2018 Malignant mesothelioma, are neutrophil/lymphocyte ratio and platelet/lymphocyte ratio prognostic indicator parameters as reliable? Source: International Congress 2015 – Mediastinal tumors, malignant pleural mesothelioma and other rare tumors Year: 2015 Prognostic value of neutrophil-to-lymphocyte ratio in hospitalized patients with COVID-19 Source: Virtual Congress 2021 – COVID - 19 Year: 2021 The prognostic impact of the neutrophil-to-lymphocyte ratio (NLR) and platelet-to-lymphocyte ratio (PLR) in patients with non-small cell lung cancer Source: International Congress 2016 – Lung cancer and immune cells: friends or foes? Year: 2016 Lipocalin-2: a biomarker potentially associated with predisposition to COPD Source: Virtual Congress 2020 – Cellular stress in respiratory diseases Year: 2020 Towards the next stage of novel biomarker discussion in COPD: Tekizai-Tekisho Source: Eur Respir J 2014; 43: 322-324 Year: 2013 Is it useful CD4+CD103+/CD4+ ratio for the diagnosis of lung sarcoidosis? Source: Annual Congress 2011 - Diagnosis and treatment of inflammatory respiratory diseases Year: 2011 Microalbuminuria as a potential novel cardiovascular biomarker in patients with COPD Source: Eur Respir J 2014; 43: 951-953 Year: 2014 The new prognostic multidimensional index HODEH in patient with COPD Source: Annual Congress 2008 - Prognosis in COPD Year: 2008 Prognostic value of haematological markers such as neutrophil-lymphocyte ratio (NLR) and platelet-lymphocyte ratio (PLR) in small cell lung cancer. Source: Virtual Congress 2020 – Prognostic and predictive factors: treatment of lung cancer Year: 2020 Can YKL-40 be used as a biomarker and therapeutic target for adult asthma? Source: Eur Respir J, 51 (1) 1702194; 10.1183/13993003.02194-2017 Year: 2018 C-reactive protein/albumin ratio as a prognostic biomarker in critically ill septic patients: a prospective study Source: Virtual Congress 2020 – Experimental and laboratory studies in intensive care unit medicine Year: 2020 Blood biomarkers predicting disease progression in patients with IPF: data from the INMARK trial Source: International Congress 2019 – The evolving field of idiopathic interstitial pneumonia Year: 2019